Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02921893 · ClinicalTrials.gov registry record · Early Phase 1
Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
NCT02921893: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT02921893 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02921893, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This phase II trial studies how well ixazomib citrate, lenalidomide, and dexamethasone work in treating patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving ixazomib citrate, lenalidomide, and dexamethasone may work better in treating patients with POEMS syndrome.
Interventions
- OTHER Questionnaire Administration
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Ixazomib Citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-10-31 |
| Est. Completion | 2024-05-13 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02921893
The ClinicalTrials.gov registry entry for NCT02921893 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Questionnaire Administration is the first listed.
NCT02921893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02921893 about?
NCT02921893 is a clinical study titled "Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome". This phase II trial studies how well ixazomib citrate, lenalidomide, and dexamethasone work in treating patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Ixazomib citrate may stop the growth of cancer cells by blocking some of the e...
What is the current status of trial NCT02921893?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2016-10-31. Estimated completion is 2024-05-13.
What interventions are being tested in trial NCT02921893?
The interventions under investigation include: Questionnaire Administration (OTHER), Dexamethasone (DRUG), Lenalidomide (DRUG), Ixazomib Citrate (DRUG).
Who is sponsoring clinical trial NCT02921893?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.